XmAb 13676
Cancer
ClinicalActive (with Novartis)
Key Facts
About Xencor
Xencor is a publicly traded biotechnology company focused on redesigning antibody drugs from the ground up using its core XmAb Fc domain engineering platform. The company has established a robust pipeline of over 20 clinical-stage programs and has successfully partnered its technology, resulting in three marketed drugs. Xencor's strategy combines proprietary drug development in oncology and autoimmunity with a prolific licensing model that extends its technology to major pharmaceutical partners.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Shared Antigen mRNA Cancer Vaccines | BioNTech | Phase 2 |
| Targeted Oncology Therapies | BioNTech | Phase 1/2 |
| ARGX-119 | Argenx | Phase 1 |
| Oncology Program | Shionogi | Clinical |
| Bmab (Bevacizumab) | Biocon | Approved |
| Ciforadenant (CPI-444) | Corvus Pharmaceuticals | Phase 1/2 |
| Mupadolimab (CPI-006) | Corvus Pharmaceuticals | Phase 1 |
| tovecimig | Compass Therapeutics | Clinical |
| CTX-8371 | Compass Therapeutics | Clinical |
| XmAb 14045 | Xencor | Clinical |
| Vibostolimab | Xencor | Clinical |
| PB272 (neratinib, intravenous) | Puma Biotechnology | Not Disclosed |